Immunotherapy with anti-CD20 compounds

Seminars in Cancer Biology

Volumn 13, Issue 3, 2003, Pages 211-222

  Von Schilling, Christoph ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

B cell lymphoma; CD20; Clinical trials; Monoclonal antibody

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; CHLORAMBUCIL; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; RITUXIMAB;

ALLERGIC REACTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOTHERAPY; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; REVIEW; SURVIVAL; VASCULITIS;

EID: 0038294705     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(03)00018-X     Document Type: Review

References (182)

1. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125:1980;1678-1685.
2. Galiègue-Zouitina S., Collyn-d'Hooghe M., Denis C., Mainardi A., Hildebrand M.P., Tilly H.et al. Molecular cloning of a t(11;14)(q13;q32) translocation breakpoint centromeric to the Bcl-1-MTC. Genes Chromosomes Cancer. 11:1994;246-255.
3. Noordzij J.G., de Bruin-Versteeg S., Comans-Bitter W.M., Hartwig N.G., Hendriks R.W., de Groot R.et al. Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children. Pediatr. Res. 51:2002;159-168.
4. Rieckmann P., Thévenin C., Wilson G.L., Hong J.X., Kehrl J.H. Analysis of cis-acting elements present in the CD20/B1 antigen promoter. J. Immunol. 147:1991;3994-3999.
5. Thevenin C., Lucas B.P., Kozlow E.J., Kehrl J.H. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J. Biol. Chem. 268:1993;5949-5956.
6. Kehrl J.H., Riva A., Wilson G.L., Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol. Today. 15:1994;432-436.
7. Himmelmann A., Riva A., Wilson G.L., Lucas B.P., Thevenin C., Kehrl J.H. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood. 90:1997;3984-3989.
8. Warzynski M.J., Graham D.M., Axtell R.A., Zakem M.H., Rotman R.K. Low level CD20 expression on T cell malignancies. Cytometry. 18:1994;88-92.
9. Hultin L.E., Hausner M.A., Hultin P.M., Giorgi J.V. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 14:1993;196-204.
10. Tedder T.F., Streuli M., Schlossman S.F., Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 85:1988;208-212.
11. 2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121:1993;121-1132.
12. Polyak M.J., Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 99:2002;3256-3262.
13. O'Keefe T.L., Williams G.T., Davies S.L., Neuberger M.S. Mice carrying a CD20 gene disruption. Immunogenetics. 48:1998;125-132.
14. Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B-lymphocytes. Immunol. Today. 15:1994;450-454.
15. Golay J.T., Clark E.A., Beverley P.C. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. 35:1985;3795-3801.
16. Bourget I., Breittmayer J.P., Grenier-Brossette N., Cousin J.L. CD20 monoclonal antibodies down-regulate IgM at the surface of B cells. Eur. J. Immunol. 23:1993;768-771. [CD20 activation reduces sIgM expression via PKC-dependent pathway and therefore prevents further activation by BCR-mediated signalling].
17. Petrie R.J., Deans J.P. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J. Immunol. 169:2002;2886-2891.
18. Holder M., Grafton G., MacDonald I., Finney M., Gordon J. Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur. J. Immunol. 25:1995;3160-3164.
19. Kanzaki M., Lindorfer M.A., Garrison J.C., Kojima I. Activation of the calcium-permeable cation channel CD20 by alpha subunits of the Gi protein. J. Biol. Chem. 272:1997;14733-14739.
20. Kanzaki M., Shibata H., Mogami H., Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J. Biol. Chem. 270:1995;13099-13110.
21. Riley J.K., Sliwkowski M.X. CD20: a gene in search of a function. Semin. Oncol. 27:2000;17-24.
22. Tedder T.F., Schlossman S.F. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B-lymphocytes. J. Biol. Chem. 263:1988;10009-10015.
23. Leveille C., Castaigne J.G., Charron D., Al-Daccak R. MHC class II isotype-specific signaling complex on human B cells. Cancer Res. 60:2000;7170-7177.
24. Leveille C., Al-Daccak R., Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 in human B cell lines. Eur. J. Immunol. 29:1999;65-74 Valentine M.A., Meier K.E., Rossie S., Clark E.A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J. Biol. Chem. 264:1989;11282-11287.
25. Leveille C., Al-Daccak R., Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 in human B cell lines. Eur. J. Immunol. 29:1999;65-74 Valentine M.A., Meier K.E., Rossie S., Clark E.A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J. Biol. Chem. 264:1989;11282-11287.
26. Deans J.P., Kalt L., Ledbetter J.A., Schieven G.L., Bolen J.B., Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J. Biol. Chem. 270:1995;22632-22638.
27. Deans J.P., Schieven G.L., Shu G.L., Valentine M.A., Gilliland L.A., Aruffo A.et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and phospholipase C-gamma 2. J. Immunol. 151:1993;4494-4504.
28. Popoff I.J., Savage J.A., Blake J., Johnson P., Deans J.P. The association between CD20 and src-family tyrosine kinases requires an additional factor. Mol. Immunol. 35:1998;207-214.
29. Brdicka T., Pavlistova D., Leo A Bruyns E., Korinek V., Angelisova P., Scherer J.et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J. Exp. Med. 191:2000;1591-1604.
30. Mathas S., Rickers A., Bommert K., Dörken B., Mapara M.Y. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Eur. J. Immunol. 32:2002;2282-2291.
31. White M.W., McConnell F., Shu G.L., Morris D.R., Clark E.A. Activation of dense human tonsillar B cells Induction of c-myc gene expression via two distinct signal transduction pathways. J. Immunol. 146:1991;846-853.
32. Ghetie M.A., Bright H., Vitetta E.S. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 97:2001;1392-1398.
33. Rossmann E.D., Lundin J., Lenkei R., Mellstedt H., Österborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol. J. 2:2001;300-306.
34. Gatter KC, Warnke RA. Diffuse large B cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
35. Kennedy G.A., Tey S.K., Cobcroft R., Marlton P., Cull G., Grimmett K.et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br. J. Haematol. 119:2002;412-416.
36. Foran J.M., Norton A.J., Micallef I.N., Taussig D.C., Amess J.A., Rohatiner A.Z.et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br. J. Haematol. 114:2001;881-883.
37. Nadler L.M., Takvorian T., Botnick L., Bast R.C., Finberg R., Hellman S.et al. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 2:1984;427-431.
38. Press O.W., Appelbaum F., Ledbetter J.A., Martin P.J., Zarling J., Kidd P.et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 69:1987;584-591.
39. 131I ]anti-B1 (anti-CD20) antibody N. Engl. J. Med. 329:1993;459-465.
40. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger C.C., Nelp W.B.et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329:1993;1219-1224.
41. Knox S.J., Goris M.L., Trisler K., Negrin R., Davis T., Liles T.M.et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2:1996;457-470.
42. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Rabb R.et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:1994;435-445.
43. Anderson D.R., Grillo-López A., Varns C., Chambers K.S., Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25:1997;705-708.
44. Harjunpaa A., Junnikkala S., Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51:2000;634-641.
45. Stockmeyer B., Dechant M., van Egmond M., Tutt A.L., Sundarapandiyan K., Graziano R.F.et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J. Immunol. 165:2000;5954-5961.
46. Davies J., Jiang L., Pan L.Z., LaBarre M.J., Anderson D., Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74:2001;288-294.
47. Deans J.P., Robbins S.M., Polyak M.J., Savage J.A. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J. Biol. Chem. 273:1998;344-348.
48. Deans J.P., Li H., Polyak M.J. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 107:2002;176-182.
49. Semac I., Palomba C., Kulangara K., Klages N., van Echten-Deckert G., Borisch B.et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 63:2003;534-540.
50. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W.et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 101:2003;1045-1052.
51. Bellosillo B., Villamor N., López-Guillermo A., Marcé S., Bosch F., Campo E.et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 98:2001;2771-2777.
52. van der Kolk L.E., Evers L.M., Omene C., Lens S.M., Lederman S., van Lier R.A.et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia. 16:2002;1735-1744.
53. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 91:1998;1644-1652.
54. Shan D., Ledbetter J., Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48:2000;673-683.
55. Hofmeister J.K., Cooney D., Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26:2000;133-143.
56. Flieger D., Renoth S., Beier I., Sauerbruch T., Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 204:2000;55-63.
57. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 99:2002;1314-1319.
58. Alas S., Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61:2001;5137-5144.
59. Weng W.K., Levy R. Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma. Blood. 100:2002;157a. [abstract 590].
60. Selenko N., Maidic O., Draxier S., Berer A., Jäger U., Knapp W.et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. 15:2001;1619-1626.
61. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-López A.et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 84:1994;2457-2466.
62. Maloney D.G., Grillo-López A.J., Bodkin D.J., White C.A., Liles T.M., Royston I.et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15:1997;3266-3274.
63. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A.et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
64. McLaughlin P., Grillo-López A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E.et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:1998;2825-2833.
65. Foran J.M., Gupta R.K., Cunningham D., Popescu R.A., Goldstone A.H., Sweetenham J.W.et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109:2000;81-88.
66. Ghielmini M., Schmitz S.F., Bürki K., Pichert G., Betticher D.C., Stupp R.et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 11(Suppl. 1):2000;123-126.
67. Feuring-Buske M., Kneba M., Unterhalt M., Engert A., Gramatzki M., Hiller E.et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann. Hematol. 79:2000;493-500.
68. Igarashi T., Kobayashi Y., Ogura M., Kinoshita T., Ohtsu T., Sasaki Y.et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann. Oncol. 13:2002;928-943.
69. Foran J.M., Rohatiner A.Z., Cunningham D., Popescu R.A., Solal-Céligny P., Ghielmini M.et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 18:2000;317-324.
70. Dimopoulos M.A., Zervas C., Zomas A., Kiamouris C., Viniou N.A., Grigoraki V.et al. Treatment of Waldenström's macroglobulinemia with rituximab. J. Clin. Oncol. 20:2002;2327-2333.
71. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V.et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 97:2001;101-106.
72. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D.et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 92:1998;1927-1932.
73. Tsai D., Moore H., Hardy C., Porter D., Loh E., Vaughn D.et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant. 24:1999;521-526.
74. Piro L.D., White C.A., Grillo-López A.J., Janakiraman N., Saven A., Beck T.M.et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10:1999;655-661.
75. Hainsworth J.D., Litchy S., Burris H.A. III, Scullin D.C. Jr., Corso S.W., Yardley D.A.et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2002;4261-4267.
76. Ghielmini M., Schmitz S.F.H., Cogliatti S., Pichert G., Fey M., Betticher D.et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood. 100:2002;161a.
77. Huhn D., von Schilling C., Wilhelm M., Ho A.D., Hallek M., Kuse R.et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 98:2001;1326-1331.
78. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freireich E.J., Cortes J.et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19:2001;2165-2170.
79. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K.et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19:2001;2153-2164.
80. Hagberg H., Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br. J. Haematol. 115:2001;609-611.
81. Lauria F., Lenoci M., Annino L., Raspadori D., Marotta G., Bocchia M.et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica. 86:2001;1046-1050.
82. Maloney D.G. Preclinical and phase I and II trials of rituximab. Semin. Oncol. 26:1999;74-78.
83. Davis T.A., White C.A., Grillo-López A.J., Velasquez W.S., Link B., Maloney D.G.et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 17:1999;1851-1857.
84. Foran J.M., Cunningham D., Coiffier B., Solal-Céligny P., Reyes F., Ghielmini M.et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann. Oncol. 11(Suppl. 1):2000;117-121.
85. Berinstein N.L., Grillo-López A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M.et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9:1998;995-1001.
86. Tobinai K., Kobayashi Y., Narabayashi M., Ogura M., Kagami Y., Morishima Y.et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 study group. Ann. Oncol. 9:1998;527-534.
87. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S.et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 95:2000;3900-3908.
88. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T.et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 98:2001;3383-3389.
89. Weng W.K., Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 98:2001;1352-1357.
90. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C.et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 101:2003;949-954.
91. Cartron G., Dacheux L., Salles G., Solal-Céligny P., Bardos P., Colombat P.et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 99:2002;754-758. [single nucleotide polymorphism (SNP) of IgG Fc receptor FcRIIIa (FCGR3A) molecule affects clinical outcome of anti-CD20 monoclonal antibody therapy for follicular non-Hodgkin lymphoma].
92. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J.et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:2003;455-459.
93. Bohen SP, Troyanskaya OG, Alter O, Warnke R, Botstein D, Brown PO, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003;5 [epub ahead of print].
94. Ghia P., Granziero L., Chilosi M., Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Semin. Cancer Biol. 12(2):2002;149-155.
95. Byrd J.C., Smith L., Hackbarth M.L., Flinn I.W., Young D., Proffitt J.H.et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 63:2003;36-38.
96. 131I -anti-CD20 therapy J. Clin. Oncol. 17:1999;3692-3693.
97. Schmitz K., Brugger W., Weiss B., Kaiserling E., Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br. J. Haematol. 106:1999;571-572.
98. Davis T.A., Grillo-López A.J., White C.A., McLaughlin P., Czuczman M.S., Link B.K.et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18:2000;3135-3143.
99. Coiffier B., Bouaffia F., Thieblemont C., Hequet O., Arnaud P., Dumontet C.et al. Rituximab re-treatment in B-cell lymphoma patients: efficacy and toxicity in 59 patients treated in one center. Blood. 100:2002;360a. [abstract 1390].
100. Alas S., Ng C.P., Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin. Cancer Res. 8:2002;836-845.
101. Alas S., Bonavida B., Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res. 20:2000;2961-2966.
102. Johnson T.A., Press O.W. Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int. J. Cancer. 85:2000;104-112.
103. Di Gaetano N., Xiao Y., Erba E., Bassan R., Rambaldi A., Golay J.et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114:2001;800-809.
104. Rose A.L., Smith B.E., Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 100:2002;1765-1773.
105. Coiffier B., Lepage E., Brière J., Herbrecht R., Tilly H., Bouabdallah R.et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:2002;235-244.
106. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin. Oncol. 29(2 Suppl. 6):2002;18-22.
107. Mounier N, Brière J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003 [epub ahead of print].
108. Wilson W.H., Gutiérrez M., O'Connor P., Frankel S., Jaffe E., Chabner B.A.et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin. Oncol. 29(Suppl. 2):2002;41-47.
109. Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-López A., Gilman P.et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 19:2001;389-397.
110. Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-López A., Benyunes M.et al. Long term follow-up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Blood. 100:2002;361a. [abstract 1396].
111. Tirelli U., Spina M., Jaeger U., Nigra E., Blanc P.L., Liberati A.M.et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res. 159:2002;149-153.
112. Kewalramani T., Zelenetz A., Bertino J., Donnelly G., Hedrick E., Noy A.et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood. 98:2001;346a. [abstract 1459].
113. Czuczman M.S., Grillo-López A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F.et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17:1999;268-276.
114. Czuczman M.S., Fallon A., Mohr A., Stewart C., Bernstein Z.P., McCarthy P.et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Oncol. 29(Suppl. 2):2002;36-40.
115. Martinelli G., Laszlo D., Mancuso P., Santoro P., Pruneri G., Vanazzi A.et al. Rituximab plus chlorambucil in low-grade non-Hodgkin's lymphoma (NHL): a phase II study. Blood. 100:2002;794a. [abstract 3073].
116. Vitolo U., Boccomini C., Ladetto M., Rota-Scalabrini D., Pogliani E., Rigacci L.et al. High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemo-immunotherapy FND + rituximab. Blood. 100:2002;359a. [abstract 1392].
117. Cohen A., Polliack A., Ben-Bassat I., Avigdor A., Bennett M., Berkowicz M.et al. Results of a phase II study employing a combination of fludarabine, cyclophosphamide, and rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): the Israel Cooperative Lymphoma Group. Blood. 100:2002;360a. [abstract 1393].
118. Levine A.M., Espina B.M., Mohrbacher A., Buchanan L.H., Berman N., Mark L.et al. Fludarabine, mitoxantrone and rituxan: an effective regimen for the treatment of mantle cell lymphoma. Blood. 100:2002;361a. [abstract 1399].
119. Gregory S.A., Venugopal P., Adler S., Enschede S., Yunus F., O'Brien T.M.et al. Combined fludarabine, mitoxantrone and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin's lymphoma (LGNHL). Blood. 100:2002;362. [abstract 1401].
120. Maloney D.G., Press O.W., Braziel R.M., Unger J.M., LeBlanc M.L., Grogan T.M.et al. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Blood. 98:2001;843a. [abstract 3502].
121. Howard O.M., Gribben J.G., Neuberg D.S., Grossbard M., Poor C., Janicek M.J.et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 20:2002;1288-1294.
122. Schulz H., Klein S.K., Rehwald U., Reiser M., Hinke A., Knauf W.U.et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 100:2002;3115-3120.
123. Byrd J.C., Peterson B.L., Morrison V.A., Park K., Jacobson R., Hoke E.et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101:2003;6-14.
124. Zinzani PL, on behalf of an Italian Cooperative Group on Lymphoma. A multicenter randomised trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Blood 2002;100:93a [abstract 344].
125. Hiddemann W., Unterhalt M., Dreyling M., Hossfeld D.K., Lengfelder E., Metzner B.et al. The addition of rituximab (R) combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood. 100:2002;92a. [abstract 339].
126. Herold M., Fiedler F., Pasold R., Knauf W., Freund M., Naumann R.et al. Efficacy and toxicity of rituximab plus mitoxantrone, chlorambucil, prednisolone (MCP) versus MCP alone in advanced indolent NHL - interim results of a clinical phase III study of the East German Group Hematology/Oncology. Blood. 98:2001;601a. [abstract 2521].
127. Lefrère F., Delmer A., Suzan F., Levy V., Belanger C., Djabarri M.et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 16:2002;587-593.
128. Bole J., Li Y., Tsukada N., Kipps T.J. Combined rituximab and high-dose methylprednisolone for the treatment of chronic lymphocyticleukemia. Blood. 100:2002;802a. [abstract 3166].
129. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003 [epub ahead of print].
130. Magni M., Di Nicola M., Devizzi L., Matteucci P., Lombardi F., Gandola L.et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 96:2000;864-869.
131. Voso M.T., Pantel G., Weis M., Schmidt P., Martin S., Moos M.et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br. J. Haematol. 109:2000;729-735.
132. Berkahn L., Simpson D., Raptis A., Klingemann H.G. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia. J. Hematother. Stem Cell. Res. 11:2002;315-320.
133. Flohr T., Hess G., Kolbe K., Gamm H., Nolte H., Stanislawski T.et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant. 29:2002;769-775.
134. Lazzarino M., Arcaini L., Bernasconi P., Alessandrino E.P., Gargantini L., Cairoli R.et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br. J. Haematol. 116:2002;229-235.
135. Gianni A.M., Cortelazzo S., Magni M., Martelli M. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant. 29(Suppl. 1):2002;S10-13.
136. Brugger W., Hirsch J., Repp R., Grünebach F., Schlimok G., Vogel W.et al. Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: a multicenter phase II study. Blood. 100:2002;644a. [2532].
137. Ladetto M., Zallio F., Vallet S., Ricca I., Cuttica A., Caracciolo D.et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia. 15:2001;1941-1949.
138. Horwitz S.M., Negrin R.S., Stockerl-Goldstein K.E., Johnston L.J., Shizuru J.A., Stuart M.J.et al. Phase II trial of rituximab as adjuvant
139. Mangel J., Buckstein R., Imrie K., Spaner D., Crump M., Tompkins K.et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin. Oncol. 29(1 Suppl. 2):2002;56-69.
140. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115:2001;807-811.
141. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab IDEC-C2B8). Blood. 94:1999;2217-2224.
142. Lim L.C., Koh L.P., Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J. Clin. Oncol. 17:1999;1962-1963.
143. Kunzmann V., Rüdiger T., Hallek M., Mueller-Hermelink H.K., Wilhelm M. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood. 98:2001;1991-1992.
144. Byrd J.C., Waselenko J.K., Maneatis T.J., Murphy T., Ward F.T., Monahan B.P.et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17:1999;791-795.
145. Dereure O., Navarro R., Rossi J.F., Guilhou J.J. Rituximab-induced vasculitis. Dermatology. 203:2001;83-84.
146. Maeda T., Yamada Y., Tawara M., Yamasaki R., Yakata Y., Tsutsumi C.et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int. J. Hematol. 74:2001;70-75.
147. van der Kolk L.E., Baars J.W., Prins M.H., van Oers M.H. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 100:2002;2257-2259.
148. Matteucci P., Magni M., Di Nicola M., Carlo-Stella C., Uberti C., Gianni A.M. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 100:2002;1104-1105.
149. Goldberg S.L., Pecora A.L., Alter R.S., Kroll M.S., Rowley S.D., Waintraub S.E.et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood. 99:2002;1486-1488.
150. Quartier P., Tournilhac O., Archimbaud C., Lazaro L., Chaleteix C., Millet P.et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin. Infect. Dis. 36:2003;e47-49.
151. Buckstein R., Imrie K., Spaner D., Potichnyj A., Robinson J.B., Nanji S.et al. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin. Oncol. 26(Suppl. 14):1999;115-122.
152. Wiseman G.A., White C.A., Stabin M., Gordon L., Emmanouilides C., Rabitschek A.et al. Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs [abstract]. J. Clin. Oncol. 18:1999;4a.
153. Kaminski M.S., Zasadny K.R., Francis I.R., Fenner M.C., Ross C.W., Milik A.W.et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14:1996;1974-1981.
154. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood. 96:2000;1259-1266.
155. Witzig T.E., White C.A., Wiseman G.A., Gordon L.I., Emmanouilides C., Raubitschek A.et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17:1999;3793-3803.
156. Wiseman G.A., Gordon L.I., Multani P.S., Witzig T.E., Spies S., Bartlett N.L.et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 99:2002;4336-4342.
157. Vose J.M., Wahl R.L., Saleh M., Rohatiner A.Z., Knox S.J., Radford J.A.et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 18:2000;1316-1323.
158. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R.et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2002;2453-2463.
159. Witzig T.E., Flinn I.W., Gordon L.I., Emmanouilides C., Czuczman M.S., Saleh M.N.et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2002;3262-3269.
160. Press O.W., Unger J.M., Braziel R.M., Maloney D.G., LeBlanc M.L., Grogan T.M.et al. A phase II trial of CHOP followed by Bexxar™ (tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911). Blood. 98:2001;843a-844a. [abstract 3504].
161. Wiseman G.A., Colgan J.P., Inwards D.J., Micallef I.N.M., Porrata L.F., Gansen D.N.et al. Yttrium-90 Zevalin phase I sequential radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkin's lymphoma (NHL): preliminary results. Blood. 100:2002;358a. [abstract 1387].
162. 131I -B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet. 346:1995;336-340.
163. Liu S.Y., Eary J.F., Petersdorf S.H., Martin P.J., Maloney D.G., Appelbaum F.R.et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol. 16:1998;3270-3278.
164. Press O.W., Eary J.F., Gooley T., Gopal A.K., Liu S., Rajendran J.G.et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 96:2000;2934-2942.
165. Gopal A.K., Rajendran J.G., Petersdorf S.H., Maloney D.G., Eary J.F., Wood B.L.et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 99:2002;3158-3162.
166. Behr T.M., Griesinger F., Riggert J., Gratz S., Behe M., Kaufmann C.C.et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer. 94(4 Suppl.):2002;1363-1372.
167. Vose J.M., Bierman P.J., Lynch J.C., Gobar L., Augustine S., Dukat V.et al. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): synergistic results with no added toxicity. J. Clin. Oncol. 20:2001;6a. [abstract 19].
168. Winter J.N., Inwards D., Erwin W., Wiseman G., Rademaker A., Patton D.R.et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood. 100:2002;411a. [abstract 1597].
169. Bennett J.M., Zelenetz A.D., Press O.W., Vose J.M., Radford J.A., Knox S.J.et al. Incidence of myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with Bexxar™ Blood. 98:2001;335a. [abstract 1416].
170. Kuehnle I., Huls M.H., Liu Z., Semmelmann M., Krance R.A., Brenner M.K.et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 95:2000;1502-1505.
171. Milpied N., Vasseur B., Parquet N., Garnier J.L., Antoine C., Quartier P.et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann. Oncol. 11(Suppl. 1):2000;113-116.
172. Faye A., Quartier P., Reguerre Y., Lutz P., Carret A.S., Dehee A.et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br. J. Haematol. 115:2001;112-118.
173. Oertel S.H.K., Zeidler K., Grefer J., Reinke P., Jonas S., Verschuuren S.et al. Monotherapy with the anti-CD20 antibody rituximab (ritux) in patients with post-transplant lymphoproliferative disease (PTLD): results of a multicentre phase II study. Blood. 100:2002;573a. [abstract 2250].
174. Rehwald U., Schulz H., Reiser M., Sieber M., Staak J.O., Morschhauser F.et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 101:2003;420-424.
175. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, et al. Rituximab in lymphocyte predominant Hodgkin's disease: results of a phase II trial. Blood 2003 [epub ahead of print].
176. Younes A., Fayad L., McLaughlin P., Goy A.H., Romaguera J., Rodriguez M.A.et al. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin's disease. Blood. 100:2002;308b. [abstract 4774].
177. Friedberg J.W., Neuberg D., Gribben J.G., Fisher D.C., Canning C., Koval M.et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. 117:2002;828-834.
178. Ansell S.M., Witzig T.E., Kurtin P.J., Sloan J.A., Jelinek D.F., Howell K.G.et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 99:2002;67-74.
179. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M.et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:2001;2571-2575.
180. Kennedy A.D., Solga M.D., Schuman T.A., Chi A.W., Lindorfer M.A., Sutherland W.M.et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 101:2003;1071-1079.
181. Press O.W., Corcoran M., Subbiah K., Hamlin D.K., Wilbur D.S., Johnson T.et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 98:2001;2535-2544.
182. Weiden P.L., Breitz H.B., Press O., Appelbaum J.W., Bryan J.K., Gaffigan S.et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother. Radiopharm. 15:2000;15-29.